



For Immediate Release

September 23, 2019

ENDOCAN SOLUTIONS RECEIVES NOTICE OF CLAIM

Vancouver, B.C., September 23, 2019 – Endocan Solutions Inc. (CSE: WWM-Delisted) (the “Company” or “Endocan”) announces that it has received a notice of claim filed in the Supreme Court of British Columbia by Agilis Capital Corporation and Robert Van Santen (the “Plaintiffs”) alleging that the Plaintiffs are collectively owed \$301,882 for outstanding consulting fees, severance compensation and GST together with special damages in respect to an executive services contract between the Company and the Plaintiffs having an effective date of April 10, 2017. The Company has filed a response to the claim and intends on defending it vigorously.

About Endocan Solutions Inc.

Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the CSE on December 6, 2016, was subsequently put under new management, and has recently undergone a name change and share consolidation. The Company has recently brought required filings up to date under National Instrument 51-102, which includes audited annual financial statements with accompanying MD&A and Officer Certificates for the years ended October 31, 2015, 2016, 2017 & 2018. The immediate objective is to recapitalize the Company and management intends to seek and secure a suitable business acquisition and re-qualify the Company to meet the listing requirements of the Exchange.

ON BEHALF OF ENDOCAN SOLUTIONS INC.

(signed) “Bruce Clark”
Chief Executive Officer

For further information, please contact:

Bruce Clark
604-401-8100

Cautionary statements

This press release contains forward-looking information based on current expectations. Statements about the Company's expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Endocan Solutions assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.